Aberdeen Group’s Caris Life Sciences CAI Stock Holding History

Aberdeen Group’s Portfolio CAI Stock Details CAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-117,841	Closed	-$3.15M	–	990
2025 Q2	$3.15M	Buy	+117,841	New	+$3.18M	0.01%	742

Other funds holding CAI

SSP

Sixth Street Partners Dallas, Texas $711M AUM 9.3% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Aberdeen Group's CAI Position: Q3 2025 in Review

Aberdeen Group sold out of Caris Life Sciences (CAI) in Q3 2025, closing a stake of 117,841 shares — an estimated $3.15M sold.

Aberdeen Group first reported a position in CAI in Q2 2025 and held it in 1 quarter. The position peaked at $3.15M in Q2 2025. 138 funds tracked by Wall St. Rank hold CAI as of Q3 2025.

Aberdeen Group reported no remaining Caris Life Sciences position as of Q3 2025 after selling out during the quarter.
Aberdeen Group sold 117,841 Caris Life Sciences shares in Q3 2025, an estimated $3.15M.
Aberdeen Group first reported a position in Caris Life Sciences in Q2 2025 and held it in 1 quarter.
Aberdeen Group's Caris Life Sciences position peaked at $3.15M in Q2 2025.
138 funds tracked by Wall St. Rank held Caris Life Sciences as of Q3 2025.

Based on Aberdeen Group's 13F filing for Q3 2025, filed 7 Nov 2025.